CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Ding, Qiang ^a   Miyazaki, Yumi ^a   Tsukasa, Koichiro ^a   Matsubara, Shyuichiro ^a   Yoshimitsu, Makoto ^a   Takao, Sonshin ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Cancer metastasis; CD133; Epithelial mesenchymal transition (EMT); ERK1 2; N cadherin; Pancreatic cancer

Indexed keywords

ANIMALS; ANTIGENS, CD; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; GLYCOPROTEINS; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PEPTIDES; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84892881387     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-15     Document Type: Article

References (25)

1. Hidalgo M. Pancreatic cancer. N Engl J Med 2010, 362:1605-1617. 10.1056/NEJMra0901557, 20427809.
2. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454. 10.1038/nrc822, 12189386.
3. Bao B, Wang Z, Ali S, Kong D, Banerjee S, Ahmad A, Li Y, Azmi AS, Miele L, Sarkar FH. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem 2011, 112:2296-2306. 10.1002/jcb.23150, 3155646, 21503965.
4. Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, Sphyris N, Shariati M, Kumar SV, Battula VL, et al. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res 2013, 73:1981-1992. 10.1158/0008-5472.CAN-12-2962, 23378344.
5. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
6. Javle MM, Gibbs JF, Iwata KK, Pak Y, Rutledge P, Yu J, Black JD, Tan D, Khoury T. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol 2007, 14:3527-3533. 10.1245/s10434-007-9540-3, 17879119.
7. He X, Zheng Z, Li J, Ben Q, Liu J, Zhang J, Ji J, Yu B, Chen X, Su L, et al. DJ-1 promotes invasion and metastasis of pancreatic cancer cells by activating SRC/ERK/uPA. Carcinogenesis 2012, 33:555-562. 10.1093/carcin/bgs002, 22223849.
8. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003, 22:337-358. 10.1023/A:1023772912750, 12884910.
9. Chen YS, Wu MJ, Huang CY, Lin SC, Chuang TH, Yu CC, Lo JF. CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PLoS One 2011, 6:e28053. 10.1371/journal.pone.0028053, 3225383, 22140506.
10. Boivin D, Labbe D, Fontaine N, Lamy S, Beaulieu E, Gingras D, Beliveau R. The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry 2009, 48:3998-4007. 10.1021/bi900159d, 19296573.
11. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009, 106:16281-16286. 10.1073/pnas.0905653106, 2741477, 19805294.
12. Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, Natsugoe S, Aikou T, Takao S. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008, 98:1389-1397. 10.1038/sj.bjc.6604307, 2361715, 18349830.
13. Ding Q, Yoshimitsu M, Kuwahata T, Maeda K, Hayashi T, Obara T, Miyazaki Y, Matsubara S, Natsugoe S, Takao S. Establishment of a highly migratory subclone reveals that CD133 contributes to migration and invasion through epithelial-mesenchymal transition in pancreatic cancer. Hum Cell 2012, 25:1-8. 10.1007/s13577-011-0037-9, 22109279.
14. Takao S, Ding Q, Matsubara S. Pancreatic cancer stem cells: regulatory networks in the tumor microenvironment and targeted therapy. J Hepatobiliary Pancreat Sci 2012, 19:614-620. 10.1007/s00534-012-0547-1, 22878838.
15. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol 1999, 147:631-644. 10.1083/jcb.147.3.631, 2151177, 10545506.
16. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007, 13:7003-7011. 10.1158/1078-0432.CCR-07-1263, 18056176.
17. Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M, Tlsty TD. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci U S A 2008, 105:14867-14872. 10.1073/pnas.0807146105, 2567459, 18806226.
18. Na DC, Lee JE, Yoo JE, Oh BK, Choi GH, Park YN. Invasion and EMT-associated genes are up-regulated in B viral hepatocellular carcinoma with high expression of CD133-human and cell culture study. Exp Mol Pathol 2011, 90:66-73. 10.1016/j.yexmp.2010.10.003, 20969862.
19. Ferte C, Andre F, Soria JC. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev ClinOncol 2010, 7:367-380.
20. Hanrahan AJ, Solit DB. RAF/MEK dependence of KRAS-mutant pancreatic ductal adenocarcinomas. Cancer Discov 2012, 2:666-669. 10.1158/2159-8290.CD-12-0308, 22886659.
21. Kemper K, Versloot M, Cameron K, Colak S, De Sousa E, Melo F, De Jong JH, Bleackley J, Vermeulen L, Versteeg R, Koster J, Medema JP. Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. Clin Cancer Res 2012, 18:3132-3141. 10.1158/1078-0432.CCR-11-3066, 22496204.
22. Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001, 2:82-91. 10.1034/j.1600-0854.2001.020202.x, 11247306.
23. Giebel B, Corbeil D, Beckmann J, Hohn J, Freund D, Giesen K, Fischer J, Kogler G, Wernet P. Segregation of lipid raft markers including CD133 in polarized human hematopoietic stem and progenitor cells. Blood 2004, 104:2332-2338. 10.1182/blood-2004-02-0511, 15231568.
24. Velpula KK, Rehman AA, Chelluboina B, Dasari VR, Gondi CS, Rao JS, Veeravalli KK. Glioma stem cell invasion through regulation of the interconnected ERK, integrin alpha6 and N-cadherin signaling pathway. Cell Signal 2012, 24:2076-2084. 10.1016/j.cellsig.2012.07.002, 22789454.
25. Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N, Xu W, Cui C, Xing Y, Liu Y. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci U S A 2013, 110:6829-6834. 10.1073/pnas.1217002110, 3637720, 23569237.